These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 10328843)
21. [Canine leishmaniasis: evolution of the chemotherapeutic protocols]. Oliva G; Foglia Manzillo V; Pagano A Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724 [TBL] [Abstract][Full Text] [Related]
22. Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis. Poli A; Sozzi S; Guidi G; Bandinelli P; Mancianti F Vet Parasitol; 1997 Aug; 71(4):263-71. PubMed ID: 9299695 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog. Tassi P; Ormas P; Madonna M; Carli S; Belloli C; De Natale G; Ceci L; Marcotrigiano GO Res Vet Sci; 1994 Mar; 56(2):144-50. PubMed ID: 8191002 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and dosing regimen of aminosidine in the dog. Belloli C; Crescenzo G; Carli S; Villa R; Sonzogni O; Carelli G; Ormas P Vet Res Commun; 1996; 20(6):533-41. PubMed ID: 8950834 [TBL] [Abstract][Full Text] [Related]
25. Enhanced oral delivery of antimony from meglumine antimoniate/beta-cyclodextrin nanoassemblies. Frézard F; Martins PS; Bahia AP; Le Moyec L; de Melo AL; Pimenta AM; Salerno M; da Silva JB; Demicheli C Int J Pharm; 2008 Jan; 347(1-2):102-8. PubMed ID: 17656054 [TBL] [Abstract][Full Text] [Related]
26. Effects of therapy on haemostasis in dogs infected with Leishmania infantum, Ehrlichia canis, or both combined. Cortese L; Pelagalli A; Piantedosi D; Cestaro A; Di Loria A; Lombardi P; Avallone L; Ciaramella P Vet Rec; 2009 Apr; 164(14):433-4. PubMed ID: 19346544 [No Abstract] [Full Text] [Related]
27. The therapeutic effect of combined cryotherapy, paramomycin, and intralesional meglumine antimoniate in treating lupoid leishmaniasis and chronic leishmaniasis. Nilfrousihzadeh MA; Jaffray F; Reiszadeh MR; Ansari N Int J Dermatol; 2006 Aug; 45(8):989-91. PubMed ID: 16911395 [No Abstract] [Full Text] [Related]
28. Clinical and serological follow-up in dogs with visceral leishmaniosis treated with allopurinol and sodium stibogluconate. Pasa S; Toz SO; Voyvoda H; Ozbel Y Vet Parasitol; 2005 Mar; 128(3-4):243-9. PubMed ID: 15740861 [TBL] [Abstract][Full Text] [Related]
29. The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial. Slappendel RJ; Teske E Vet Q; 1997 Mar; 19(1):10-3. PubMed ID: 9225422 [TBL] [Abstract][Full Text] [Related]
30. Developmental toxicity of meglumine antimoniate and transplacental transfer of antimony in the rat. Miranda ES; Miekeley N; De-Carvalho RR; Paumgartten FJ Reprod Toxicol; 2006 Apr; 21(3):292-300. PubMed ID: 16271447 [TBL] [Abstract][Full Text] [Related]
31. Nodular lymphangitic subcutaneous dissemination after intralesional antimonial treatment for localized cutaneous leishmaniasis. Yébenes M; Cruz I; Cañavate C; Gilaberte M; Baena V; Pujol RM Clin Exp Dermatol; 2008 Mar; 33(2):142-4. PubMed ID: 18076691 [TBL] [Abstract][Full Text] [Related]
32. Polyarthritis associated with visceral leishmaniasis in a juvenile dog. Santos M; Marcos R; Assunção M; Matos AJ Vet Parasitol; 2006 Nov; 141(3-4):340-4. PubMed ID: 16824686 [TBL] [Abstract][Full Text] [Related]
33. Clinical follow-up examination after treatment of canine leishmaniasis. Moritz A; Steuber S; Greiner M Tokai J Exp Clin Med; 1998 Dec; 23(6):279-83. PubMed ID: 10622623 [TBL] [Abstract][Full Text] [Related]
34. Antimony determination in tissues and serum of hamsters infected with Leishmania garnhami and treated with meglumine antimoniate. Lugo de Yarbuh A; Añez N; Petit de Peña Y; Burguera JL; Burguera M Ann Trop Med Parasitol; 1994 Feb; 88(1):37-41. PubMed ID: 8192513 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniasis submitted to treatment with meglumine antimoniate. Ikeda-Garcia FA; Lopes RS; Ciarlini PC; Marques FJ; Lima VM; Perri SH; Feitosa MM Res Vet Sci; 2007 Aug; 83(1):105-8. PubMed ID: 17150234 [TBL] [Abstract][Full Text] [Related]
36. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664 [TBL] [Abstract][Full Text] [Related]
37. Analytical determination and pharmacokinetics of robenacoxib in the dog. Jung M; Lees P; Seewald W; King JN J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454 [TBL] [Abstract][Full Text] [Related]
38. Leishmania infantum: stage-specific activity of pentavalent antimony related with the assay conditions. Carrió J; de Colmenares M; Riera C; Gállego M; Arboix M; Portús M Exp Parasitol; 2000 Jul; 95(3):209-14. PubMed ID: 10964649 [TBL] [Abstract][Full Text] [Related]
39. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis. Moosavi Z; Nakhli A; Rassaii S Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282 [No Abstract] [Full Text] [Related]
40. Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis. Llanos-Cuentas A; Echevarria J; Seas C; Chang E; Cruz M; Alvarez E; Rosales E; Campos P; Bryceson A Am J Trop Med Hyg; 2007 Jun; 76(6):1128-31. PubMed ID: 17556623 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]